Exploiting sPLA2 enzymes for triggering drug release precisely at the target site, where the tumor resides, is a promising approach furnished by its applicability in vivo as well as by the large body of data already available on the activity of sPLA2 enzymes. Here, PLA2G2A is linked to neoplasm.